PMS2 and prostate carcinoma: Among all patients with CRC who had a loss of MLH1/PMS2 with BRAF V600E or MLH1 promoter hypermethylation, 2 of 16 were ultimately found to have a pathogenic germline mutation, but neither of these patients had Lynch syndrome, with one having an increased risk allele for prostate cancer.